Recombinant Mouse Tumor necrosis factor ligand superfamily member 11 (Tnfsf11)

What is Recombinant Mouse Tnfsf11 and what are its alternative names?

Recombinant Mouse Tnfsf11 is a member of the tumor necrosis factor (TNF) family, also commonly known as receptor activator of NF-kappa B ligand (RANK L), TNF-related activation-induced cytokine (TRANCE), osteoprotegrin ligand (OPGL), and osteoclast differentiation factor (ODF). It was originally identified as an immediate early gene upregulated by T cell receptor stimulation. The mouse TRANCE protein is a type II transmembrane protein consisting of 316 amino acids with a cytoplasmic domain of 48 amino acids and an extracellular domain of 247 amino acids. The extracellular domain contains two potential N-linked glycosylation sites .

What are the structural characteristics of commercially available Recombinant Mouse Tnfsf11?

Commercially available Recombinant Mouse Tnfsf11 comes in different forms with specific structural characteristics:

• E. coli-expressed version (Catalog # 462-TEC):

  • Contains amino acids Lys158-Asp316 with an N-terminal Met

  • Appears as a single band at approximately 19 kDa on SDS-PAGE under reducing conditions

  • Biological activity (ED50) for osteoclast differentiation: 0.5-2 ng/mL

• Alternative version with His-tag (Catalog # 462-TR):

  • Contains amino acids Arg72-Asp316 with an N-terminal 6-His tag

  • Appears as a single band at approximately 36 kDa on SDS-PAGE under reducing conditions

  • Biological activity (ED50) for osteoclast differentiation: 5-15 ng/mL (requires a cross-linking antibody)

What is the biological function of Tnfsf11 in normal physiology?

Tnfsf11 serves multiple critical functions in normal physiology:

• Osteoclastogenesis induction: It is a key factor in stimulating the differentiation of osteoclasts, which are essential for bone remodeling and homeostasis

• T cell growth enhancement: Promotes proliferation and survival of T lymphocytes

• Dendritic cell function: Improves the function and survival of dendritic cells

• Lymph node organogenesis: Plays a crucial role in the development and organization of lymph nodes

• Signal transduction: Activates the c-jun N-terminal kinase pathway

Tnfsf11 primarily targets RANK (receptor activator of NF-kappa B) as its signaling receptor, which undergoes receptor clustering during signal transduction. Its effects are naturally counterbalanced by osteoprotegerin, a soluble member of the TNF receptor family that acts as a decoy receptor .

How should researchers reconstitute and store Recombinant Mouse Tnfsf11 for optimal activity?

Reconstitution Protocol:

For E. coli-expressed version (462-TEC):

• Reconstitute at 100 μg/mL in sterile PBS

• If using the carrier-free version (462-TEC/CF), follow the same reconstitution concentration but be aware it lacks BSA stability enhancement

For His-tagged version (462-TR):

• Reconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin

Storage Recommendations:

• Upon receipt, immediately store according to recommended temperature

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain protein integrity

• For working solutions, store at 2-8°C for up to one month

• For long-term storage, prepare aliquots and store at -20°C to -80°C

What are the validated experimental applications for Recombinant Mouse Tnfsf11?

Based on citation evidence from multiple published studies, Recombinant Mouse Tnfsf11 has been successfully employed in the following experimental applications:

• Osteoclast differentiation assays: Most commonly used with RAW 264.7 mouse monocyte/macrophage cell line to induce osteoclastogenesis

• Bone metabolism studies: Used in research exploring pathological bone loss, arthritis-induced bone erosion, and cancer cell-mediated osteolysis

• Immune cell function assays: Applied in research examining T cell and dendritic cell biology

• Signal transduction analysis: Used to study NF-κB pathway activation and c-jun N-terminal kinase signaling

• Compound screening: Employed in evaluating the effects of potential therapeutic agents on osteoclast differentiation and function

What is the recommended protocol for inducing osteoclast differentiation using Recombinant Mouse Tnfsf11?

Standard Protocol for Osteoclast Differentiation:

• Cell Preparation:

  • Culture RAW 264.7 mouse monocyte/macrophage cells in appropriate medium (typically DMEM with 10% FBS)

  • Seed cells at a density of 1-2×10⁴ cells/well in a 96-well plate

• Tnfsf11 Treatment:

  • For E. coli-expressed rmTRANCE (462-TEC): Add at concentrations of 0.5-2 ng/mL

  • For His-tagged rmTRANCE (462-TR): Add at concentrations of 5-15 ng/mL along with 2.5 μg/mL of a cross-linking antibody (e.g., Mouse Anti-polyHistidine Monoclonal Antibody, Catalog # MAB050)

• Incubation:

  • Maintain cultures for 4-7 days, with medium changes every 2-3 days if necessary

• Assessment:

  • Evaluate osteoclast formation through TRAP (Tartrate-resistant acid phosphatase) staining

  • Analyze bone resorption capabilities using appropriate substrates (e.g., dentin slices, calcium phosphate-coated plates)

  • Measure osteoclast-specific gene expression via qPCR (e.g., TRAP, cathepsin K, calcitonin receptor)

What are the key differences between E. coli-expressed and His-tagged versions of Recombinant Mouse Tnfsf11?

These differences can significantly impact experimental outcomes. The E. coli-expressed version typically shows higher intrinsic activity, while the His-tagged version offers advantages for purification and detection but requires cross-linking for optimal function .

How does carrier-free Tnfsf11 differ from BSA-containing formulations and when should each be used?

Carrier-Free vs. BSA-Containing Formulations:

Carrier-free (CF) versions of Recombinant Mouse Tnfsf11 lack bovine serum albumin (BSA) as a carrier protein, whereas standard formulations include BSA. Understanding these differences is critical for experimental design:

BSA-Containing Formulations:

• Enhanced protein stability and increased shelf-life

• Allows for storage at more dilute concentrations

• Recommended for cell or tissue culture applications and as ELISA standards

• Formulated in a solution containing NaH₂PO₄, NaCl, and EDTA with BSA as a carrier protein

Carrier-Free Formulations:

• Lacks BSA in the formulation

• Recommended for applications where BSA might interfere with experimental outcomes

• Particularly useful for antibody production, protein conjugation, and certain sensitive detection methods

• Essential for experiments where background BSA could complicate data interpretation

• Formulated in a solution containing NaH₂PO₄, NaCl, and EDTA without BSA

What signaling pathways are activated by Tnfsf11 and how can researchers monitor these pathways?

Tnfsf11 activates several key signaling pathways through its receptor RANK:

• NF-κB Pathway:

  • Primary pathway activated by RANK-RANKL interaction

  • Monitor through:

    • IκB phosphorylation and degradation via Western blot

    • Nuclear translocation of NF-κB p65 using immunofluorescence

    • NF-κB-dependent gene expression via reporter assays or qPCR of target genes

• c-Jun N-terminal Kinase (JNK) Pathway:

  • Important for osteoclast differentiation

  • Monitor through:

    • JNK phosphorylation via Western blot

    • c-Jun phosphorylation and activity

    • AP-1 transcription factor activation using EMSA or reporter assays

• p38 MAPK Pathway:

  • Contributes to osteoclast formation and activity

  • Monitor through p38 phosphorylation and downstream target activation

• ERK Pathway:

  • Involved in osteoclast survival

  • Monitor through ERK1/2 phosphorylation and target gene induction

• Calcium Signaling:

  • Critical for osteoclast cytoskeletal reorganization

  • Monitor using calcium-sensitive fluorescent dyes or genetically encoded calcium indicators

What are common issues encountered when using Recombinant Mouse Tnfsf11 and how can they be resolved?

Issue 1: Reduced or absent biological activity

• Potential causes:

  • Protein denaturation from improper storage or handling

  • Insufficient reconstitution

  • Missing cross-linking antibody (for His-tagged version)

• Solutions:

  • Ensure proper reconstitution following manufacturer's protocol

  • Add cross-linking antibody (2.5 μg/mL) when using His-tagged Tnfsf11

  • Avoid freeze-thaw cycles; use fresh aliquots

  • Verify protein integrity via SDS-PAGE before use

Issue 2: Variation in osteoclastogenesis efficiency

• Potential causes:

  • Cell passage number affecting RAW 264.7 responsiveness

  • Batch-to-batch variation in recombinant protein

  • Suboptimal cell density

• Solutions:

  • Use lower passage RAW 264.7 cells (under passage 20)

  • Optimize cell seeding density for each experimental setup

  • Include positive controls to normalize between experiments

  • Consider titrating Tnfsf11 concentration for each new lot

Issue 3: Interfering factors in complex experimental systems

• Potential causes:

  • Presence of osteoprotegerin (OPG) in culture systems

  • Competing cytokines affecting results

• Solutions:

  • Test for OPG expression in your experimental system

  • Consider using OPG-neutralizing antibodies if necessary

  • Use carrier-free Tnfsf11 when studying interactions with other proteins

  • Implement appropriate controls for cytokine studies

How can researchers optimize Tnfsf11-induced osteoclastogenesis for specific experimental questions?

For Enhanced Osteoclast Formation:

• Supplement with M-CSF (25-50 ng/mL) alongside Tnfsf11 for primary monocyte/macrophage cultures

• Pre-treat cells with vitamin D3 (10⁻⁸ M) to upregulate RANK expression

• Optimize the cell density: higher density for RAW 264.7 cells (1-2×10⁴ cells/well) and lower density for primary bone marrow macrophages (5×10³ cells/well)

• Use E. coli-expressed Tnfsf11 (462-TEC) which requires lower concentrations for activity

• Extend culture duration to 7-10 days for more mature osteoclasts with enhanced resorptive capacity

For Studying Inhibitory Compounds:

• Use submaximal concentrations of Tnfsf11 (0.5-1 ng/mL for E. coli-expressed; 5-7 ng/mL for His-tagged)

• Consider timing of inhibitor addition (pre-treatment vs. co-treatment)

• Include appropriate vehicle controls for compounds dissolved in DMSO or ethanol

• Assess both osteoclast number and individual osteoclast activity

• Implement dose-response analysis for inhibitory compounds

What factors influence the reproducibility of Tnfsf11-dependent experiments?

Several factors can significantly affect the reproducibility of experiments using Recombinant Mouse Tnfsf11:

• Protein stability and storage:

  • Aliquot reconstituted protein to minimize freeze-thaw cycles

  • Store according to manufacturer recommendations

  • Use within the recommended time period after reconstitution

• Cell line characteristics:

  • Cell passage number influences responsiveness to Tnfsf11

  • Clone-specific variation in RAW 264.7 cells

  • Donor variation when using primary cells

• Experimental design considerations:

  • Consistent seeding density is critical

  • Timing of Tnfsf11 addition after seeding

  • Medium composition and serum batch effects

  • Presence of endogenous OPG in experimental system

• Technical variables:

  • Pipetting accuracy when working with low concentrations

  • Consistent culture conditions (CO₂, humidity, temperature)

  • Method of assessment (TRAP staining protocol, imaging parameters)

How does mouse Tnfsf11 compare to human TNFSF11 in structure and function?

Structural Similarities and Differences:

• Both are type II transmembrane proteins

• Both contain TNF homology domains in the extracellular region

• Mouse Tnfsf11 is 316 amino acids while human is slightly different in length

• N-glycosylation sites are largely conserved between species

• Species-specific differences exist in the intracellular domain

Functional Considerations:

• Both activate the same primary signaling pathways

• Cross-reactivity exists but is not complete; mouse Tnfsf11 may have reduced activity on human cells and vice versa

• Similar roles in osteoclastogenesis, though potency may differ

• Species-specific differences in expression patterns across tissues

• Differential sensitivity to certain inhibitors and therapeutic agents

These comparisons are particularly important when designing translational studies or interpreting results from mouse models for human disease applications.

What are the emerging research areas involving Tnfsf11 beyond osteoclastogenesis?

While Tnfsf11 is best known for its role in osteoclast differentiation, research has expanded into several other significant areas:

• Immune System Regulation:

  • T cell development and function

  • Dendritic cell survival and activation

  • Lymph node development and organization

  • Interactions with other immune cell types

• Cancer Biology:

  • Promotion of cancer cell-mediated osteolysis in bone metastasis

  • Direct effects on cancer cell proliferation and survival

  • Immunomodulatory effects in the tumor microenvironment

  • Potential therapeutic target in cancer-induced bone disease

• Metabolic Regulation:

  • Role in glucose metabolism

  • Influence on energy expenditure

  • Connections to obesity and metabolic syndrome

  • Glutamine-dependent energy metabolism in inflammatory conditions

• Cardiovascular Research:

  • Vascular calcification processes

  • Atherosclerotic plaque stability

  • Cardiac remodeling after injury

• Neurological Applications:

  • Neuroinflammatory processes

  • Microglial activation

  • Potential roles in neurodegenerative diseases

How can researchers effectively use Tnfsf11 in drug development and screening applications?

Recombinant Mouse Tnfsf11 serves as a valuable tool in drug development and screening, particularly for compounds targeting bone metabolism disorders:

Methodological Approaches:

• High-Throughput Screening Systems:

  • Establish standardized osteoclastogenesis assays using RAW 264.7 cells in 96- or 384-well formats

  • Implement automated TRAP staining and quantification

  • Use calcium phosphate-coated plates for simultaneous assessment of resorption activity

  • Develop reporter cell lines expressing osteoclast-specific promoters linked to luciferase

• Target Validation Strategies:

  • Compare effects on Tnfsf11-induced vs. alternative osteoclastogenesis pathways

  • Assess compound effects on different stages of osteoclast differentiation by varying treatment timing

  • Combine with genetic approaches (siRNA, CRISPR) targeting RANK pathway components

• Translational Model Systems:

  • Progress from in vitro RAW 264.7 screens to primary mouse bone marrow macrophages

  • Implement ex vivo bone organ culture systems as an intermediate step

  • Validate promising compounds in appropriate in vivo models

• Mechanistic Investigations:

  • Determine whether compounds directly interfere with Tnfsf11-RANK interaction

  • Assess effects on downstream signaling pathways using phospho-specific antibodies

  • Evaluate effects on specific osteoclast genes and proteins

  • Consider off-target effects on other TNF family members

What are the newest methodological approaches for studying Tnfsf11 biology?

Recent advances in research technology have opened new avenues for studying Tnfsf11 biology with unprecedented precision:

• CRISPR/Cas9 Genome Editing:

  • Generation of cell lines with modified RANK or downstream signaling components

  • Creation of reporter systems with endogenous tagging of Tnfsf11 pathway proteins

  • Development of conditional knockout systems for temporal control of Tnfsf11/RANK expression

• Advanced Imaging Techniques:

  • Live-cell imaging of Tnfsf11-RANK interactions using fluorescently tagged proteins

  • Super-resolution microscopy to visualize receptor clustering dynamics

  • Intravital imaging to monitor osteoclast formation and activity in vivo

• Single-Cell Analysis:

  • Single-cell RNA sequencing to identify heterogeneity in responses to Tnfsf11

  • CyTOF and spectral flow cytometry for high-dimensional protein analysis

  • Spatial transcriptomics to map Tnfsf11 signaling in tissue context

• Computational Approaches:

  • Systems biology modeling of Tnfsf11 signaling networks

  • Machine learning algorithms to predict compound effects on Tnfsf11-induced pathways

  • Bioinformatic integration of multi-omics data to identify novel regulatory mechanisms

How might Tnfsf11 research contribute to understanding and treating metabolic bone disorders?

Tnfsf11 research has significant implications for understanding and developing treatments for metabolic bone disorders:

• Osteoporosis:

  • Denosumab, a human monoclonal antibody against RANKL, demonstrates the clinical relevance of this pathway

  • Mouse models using recombinant Tnfsf11 help identify novel therapeutic targets

  • Understanding the regulation of endogenous Tnfsf11 expression can reveal new intervention points

• Rheumatoid Arthritis:

  • Tnfsf11 contributes to inflammatory bone erosion

  • Targeting TRPC channels in Tnfsf11-mediated arthritis-induced bone erosion represents a novel approach

  • Combination therapies addressing both inflammation and Tnfsf11-induced bone loss

• Cancer-Induced Bone Disease:

  • Understanding how cancer cells modulate the Tnfsf11 pathway

  • Developing strategies to inhibit cancer cell-mediated osteolysis

  • Potential for combined anti-tumor and bone-protective therapies

• Novel Therapeutic Approaches:

  • Bispecific antibodies targeting Tnfsf11 and inflammatory cytokines

  • Small molecule inhibitors of downstream signaling components

  • Anabolic agents that counter Tnfsf11 effects

  • Natural compounds like Zingerone and Artemisinin-Daumone hybrids showing promise in Tnfsf11-induced osteoclastogenesis inhibition

What quality control measures should researchers implement when working with recombinant Tnfsf11?

To ensure experimental reliability when working with Recombinant Mouse Tnfsf11, researchers should implement comprehensive quality control measures:

• Protein Verification:

  • Confirm protein integrity via SDS-PAGE analysis before use

  • Verify bioactivity using a standardized osteoclastogenesis assay

  • Consider implementing a minimum activity threshold for experimental use

• Experimental Controls:

  • Include positive controls (known osteoclastogenic factors) in each experiment

  • Use negative controls (no Tnfsf11 treatment) to establish baseline

  • Consider including inhibitor controls (OPG or anti-RANKL antibody)

• Reproducibility Measures:

  • Document lot numbers and source of recombinant protein

  • Standardize cell culture conditions and passage numbers

  • Implement consistent protocols for reconstitution and storage

  • Conduct regular testing of frozen aliquots for activity maintenance

• Advanced Validation:

  • Periodically verify protein by mass spectrometry

  • Test for endotoxin contamination that could confound inflammatory responses

  • Compare activity across different commercial sources or in-house preparations

  • Consider orthogonal assays to confirm specific Tnfsf11-dependent effects

These quality control measures are essential for maintaining experimental consistency and ensuring reliable research outcomes when working with this critical signaling protein.